BHF Secure EU Approval for CaRi-Heart®
The first-of-its-kind technology, CaRi-Heart®, was developed by spinout company Caristo Diagnostics and has the power to detect ‘invisible’ risk in people with possible heart disease by using routine heart scans already performed in clinical practice. CaRi-Heart® has now received it’s CE mark accreditation, meaning it can be used by doctors across the UK and Europe, and can be rolled out across the NHS.
Those identified at high risk of a future heart attack can be given personalised medication and monitored more closely to prevent a life-threatening event.
Each year in the UK there are hundreds of thousands of hospital visits for people experiencing chest pain. A coronary CT angiogram (CCTA) scan is the first-line test for patients with angina and is used to check for any narrowed or blocked segments in blood vessels that supply the heart. Every year around 350,000 people in the UK have a CCTA scan. However, 75 per cent of these scans do not show significant narrowing of the arteries and so people are sent home without treatment, yet some of them will have a heart attack at some point in the future. Until now, there has been no way for doctors to detect all the underlying red flags that could lead to a future heart attack.
CaRi-Heart® is a new technology that performs a deeper dive into the CCTA scans to reveal the ‘red flags’ beneath their surface, identifying the ‘ticking time bomb’ arteries that cause heart attacks. It works by using AI and deep-learning technology to produce a Fat Attenuation Index Score (FAI-Score®), which accurately measures inflammation of blood vessels in and around the heart.
The scientific work that underpins Caristo Diagnostics was initially carried out by BHF researchers at the University of Oxford. BHF supported the work through a number of translational awards, aimed at developing new technologies for direct patient benefit.
The technology was validated in a landmark BHF-funded study involving around 4,000 patients who were followed up for nine years after their original CCTA scan. They found that people with an abnormal FAI were up to nine times more likely to die of a heart attack in the next nine years than those with normal FAI readings. The study also showed that at least one third of patients who underwent a routine CCTA and were initially considered low risk had a much higher risk after CaRi-Heart® was applied to their scan. The patients would have therefore received a more targeted treatment based on the new technology.
Now, the researchers are looking at ways to use this ground-breaking technology to better predict an individual’s risk of developing stroke and diabetes by analysing routine CT scans. They are also directing their expertise towards the Covid-19 pandemic by developing an AI tool to specifically identify Covid-19 patients who are at high risk of having a future heart attack or stroke.
Professor James Leiper, BHF Associate Medical Director, said:
“The development and approval of this new AI tool is a major success story. It’s a prime example of how BHF-funded research can lay the foundations for a truly transformational advance in the diagnosis and prevention of heart and circulatory diseases.
“This research exemplifies the fundamental role medical research charities play in the translation of scientific research into the commercial and clinical sectors, which ultimately benefits the UK’s scientific ecosystem and patients with cardiovascular disease. Sadly, the pandemic has had a devastating blow to the BHF’s research spend, cutting it in half by £50 million this year alone. We need the kind support of the public more than ever to continue our life-saving research so more projects like this can get off the ground.”
People In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more